Byondis’ Post

Next week, our Senior Director Business Development and Licensing, Ivo Grgic, will be in Basel for Swiss Biotech Day to discuss our differentiated antibody-drug conjugate (ADC) technology platforms.   Our platforms combine proprietary, novel payloads with state-of-the-art linker and conjugation technologies and conditional activation to deliver innovative #ADC therapies that can overcome the limitations of current and next-generation #cancer treatments.   If you’re attending and would like to speak with Ivo about Byondis or how we can best help you to achieve your discovery and development goals, please reach out to BD@Byondis.com.   #ADCs #SwissBiotechDay #Partnering #Biotech